BIIB: Felzartamab and lupus assets advance in late-stage trials, targeting major unmet needs

The discussion highlighted a robust immunology pipeline, with felzartamab showing strong efficacy in late AMR and potential for durable disease control in IgA nephropathy and PMN. Multiple phase 3 and proof-of-concept studies are underway, and lupus programs are advancing with differentiated mechanisms and endpoints.

Based on Biogen Inc. [BIIB] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 3 2025